Prashant R Murumkar

List of Publications by Year
in descending order

55 papers	1,402 citations	331538 21 h-index	345118 36 g-index
58 all docs	58 docs citations	58 times ranked	2165 citing authors

#	Article	IF	Citations
1	Current perspective of TACE inhibitors: A review. Bioorganic and Medicinal Chemistry, 2009, 17, 444-459.	1.4	118
2	Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis. Journal of Medicinal Chemistry, 2018, 61, 8563-8593.	2.9	94
3	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonistsâ€"A perspective. Bioorganic and Medicinal Chemistry, 2010, 18, 8418-8456.	1.4	89
4	Benzylpiperidine-Linked Diarylthiazoles as Potential Anti-Alzheimerâ€™s Agents: Synthesis and Biological Evaluation. Journal of Medicinal Chemistry, 2016, 59, 5823-5846.	2.9	89
5	Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review. Mini-Reviews in Medicinal Chemistry, 2013, 13, 1607-1625.	1.1	85
6	Medicinal Chemistry Perspective of Fused Isoxazole Derivatives. Current Topics in Medicinal Chemistry, 2016, 16, 2863-2883.	1.0	74
7	Prospective therapeutic agents for obesity: Molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists. European Journal of Medicinal Chemistry, 2014, 79, 298-339.	2.6	59
8	Prodrug Designing of NSAIDs. Mini-Reviews in Medicinal Chemistry, 2009, 9, 124-139.	1.1	52
9	Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer. European Journal of Medicinal Chemistry, 2015, 105, 1-38.	2.6	51
10	Novel TACE inhibitors in drug discovery: a review of patented compounds. Expert Opinion on Therapeutic Patents, 2010, 20, 31-57.	2.4	48
11	Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors. Journal of Computer-Aided Molecular Design, 2010, 24, 143-156.	1.3	42
12	Contemporary developments in the discovery of selective factor Xa inhibitors: A review. European Journal of Medicinal Chemistry, 2016, 121, 671-698.	2.6	41
13	3D-Quantitative Structureâ€“Activity Relationship Studies on Benzothiadiazepine Hydroxamates as Inhibitors of Tumor Necrosis Factor-Î± Converting Enzyme. Chemical Biology and Drug Design, 2008, 71, 363-373.	1.5	36
14	Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: Design, synthesis, molecular modeling, and preliminary biological evaluation. Bioorganic and Medicinal Chemistry, 2009, 17, 3604-3617.	1.4	35
15	Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic Chemistry, 2017, 70, 256-266.	2.0	33
16	Development of Predictive 3Dâ€QSAR CoMFA and CoMSIA Models for Î²â€aminohydroxamic Acidâ€Derived Tumor Necrosis Factorâ€Î± Converting Enzyme Inhibitors. Chemical Biology and Drug Design, 2009, 73, 97-107.	1.5	30
17	Novel Multitarget Directed Triazinoindole Derivatives as Anti-Alzheimer Agents. ACS Chemical Neuroscience, 2019, 10, 3635-3661.	1.7	28
18	Structural Investigations of Acridine Derivatives by CoMFA and CoMSIA Reveal Novel Insight into Their Structures toward DNA G-Quadruplex Mediated Telomerase Inhibition and Offer a Highly Predictive 3D-Model for Substituted Acridines. Journal of Chemical Information and Modeling, 2009, 49, 1298-1311.	2.5	26

#	Article	IF	Citations
19	Development of highly predictive 3D-QSAR CoMSIA models for anthraquinone and acridone derivatives as telomerase inhibitors targeting G-quadruplex DNA telomere. Journal of Molecular Graphics and Modelling, 2010, 29, 229-239.	1.3	26
20	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opinion on Therapeutic Patents, 2015, 25, 1093-1116.	2.4	26
21	Novel methods and strategies in the discovery of TACE inhibitors. Expert Opinion on Drug Discovery, 2013, 8, 157-181.	2.5	23
22	Synthesis and biological evaluation of some novel pyrido[1,2-a]pyrimidin-4-ones as antimalarial agents. European Journal of Medicinal Chemistry, 2014, 79, 422-435.	2.6	22
23	Determination of structural requirements of influenza neuraminidase type A inhibitors and binding interaction analysis with the active site of A/H1N1 by 3D-QSAR CoMFA and CoMSIA modeling. MedChemComm, 2011, 2, 710.	3.5	20
24	Recent developments and strategies for the discovery of TACE inhibitors. Expert Opinion on Drug Discovery, 2020, 15, 779-801.	2.5	20
25	Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity. SAR and QSAR in Environmental Research, 2015, 26, 905-923.	1.0	19
26	Virtual screening-based identification of lead molecules as selective TACE inhibitors. Medicinal Chemistry Research, 2015, 24, 226-244.	1.1	19
27	Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity. Molecular Diversity, 2015, 19, 871-893.	2.1	15
28	Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE. European Journal of Medicinal Chemistry, 2011, 46, 5549-5555.	2.6	14
29	Drug-fortified liposomes as carriers for sustained release of NSAIDs: The concept and its validation in the animal model for the treatment of arthritis. European Journal of Pharmaceutical Sciences, 2018, 125, 11-22.	1.9	13
30	New pyrazolyl-dibenzo[b,e][1,4]diazepinones: room temperature one-pot synthesis and biological evaluation. Molecular Diversity, 2020, 24, 355-377.	2.1	13
31	Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review. Mini-Reviews in Medicinal Chemistry, 2018, 18, 1332-1353.	1.1	13
32	Three-dimensional quantitative structureâ€“activity relationship CoMFA/CoMSIA on pyrrolidine-based tartrate diamides as TACE inhibitors. Medicinal Chemistry Research, 2013, 22, 4192-4201.	1.1	12
33	New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents. Scientific Reports, 2018, 8, 1650.	1.6	12
34	Development of a credible 3D-QSAR CoMSIA model and docking studies for a series of triazoles and tetrazoles containing 11Î²-HSD1 inhibitors. SAR and QSAR in Environmental Research, 2016, 27, 265-292.	1.0	10
35	Vicinal diaryl azole-based urea derivatives as potential cholesterol lowering agents acting through inhibition of SOAT enzymes. European Journal of Medicinal Chemistry, 2017, 130, 107-123.	2.6	10
36	Advances in patented CB1 receptor antagonists for obesity. Pharmaceutical Patent Analyst, 2018, 7, 169-173.	0.4	10

#	Article	IF	Citations
37	Discovery of Anti-Malarial Agents Through Application of In Silico Studies. Combinatorial Chemistry and High Throughput Screening, 2015, 18, 151-187.	0.6	9
38	Identifying the structural features and diversifying the chemical domain of peripherally acting CB1 receptor antagonists using molecular modeling techniques. RSC Advances, 2016, 6, 1466-1483.	1.7	8
39	Gemini Amphiphile-Based Lipoplexes for Efficient Gene Delivery: Synthesis, Formulation Development, Characterization, Gene Transfection, and Biodistribution Studies. ACS Omega, 2018, 3, 11802-11816.	1.6	8
40	Selection of Suitable Protein Structure from Protein Data Bank: An Important Step in Structure-based Drug Design Studies. Mini-Reviews in Medicinal Chemistry, 2023, 23, 246-264.	1.1	8
41	A catalyst- and solvent-free multicomponent synthesis and docking study of some new antiproliferative N₅-allyl-quinolylpyrido[2,3-b][1,4]benzodiazepinone precursors. New Journal of Chemistry, 2016, 40, 4931-4939.	1.4	7
42	One-pot synthesis, biological evaluation, and docking study of new chromeno-annulated thiopyrano[2,3-c]pyrazoles. Molecular Diversity, 2016, 20, 639-657.	2.1	6
43	Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy. Archives of Biochemistry and Biophysics, 2021, 710, 108995.	1.4	4
44	Advances in Studies on Collagenase Inhibitors. Exs, 2012, 103, 83-135.	1.4	4
45	Synthesis and investigation of anti-inflammatory activity of novel nitric oxide donating hybrid drugs. Medicinal Chemistry Research, 2013, 22, 3510-3517.	1.1	3
46	Vicinal Diaryl Oxadiazoles, Oxazoles, and Isoxazoles. , 2018, , 277-303.		3
47	Development of Steroidal Aromatase Inhibitors as Potential Anti-breast Cancer Agents. Current Enzyme Inhibition, 2020, 16, 45-62.	0.3	3
48	Computational Modelling of Kinase Inhibitors as Anti-Alzheimer Agents. Neuromethods, 2018, , 347-417.	0.2	3
49	3-Substituted 1-methyl-3-benzazepin-2-ones as 5-HT_{2C} receptor agonists. RSC Advances, 2015, 5, 91908-91921.	1.7	2
50	Exploration of 6,7-dimethoxyquinazoline derivatives as dual acting Î±₁- and AT₁-receptor antagonists: synthesis, evaluation, pharmacophore & 3D-QSAR modeling and receptor docking studies. RSC Advances, 2016, 6, 30661-30682.	1.7	2
51	Vicinal Diaryl Triazoles and Tetrazoles. , 2018, , 191-219.		2
52	Synthesis of 2-substituted methylthieno [2,3-<i> d</i>]pyrimidin-4(3<i> h</i>)-ones and evaluation for antihyperlipidemic activity. Indian Journal of Pharmaceutical Sciences, 2007, 69, 605.	1.0	1
53	Design and synthesis of novel N-[3-(benzimidazol-2-ylamino)phenyl]amine and N-[3-(benzoxazol-2-ylamino)phenyl]amine derivatives as potential anticancer agents. Molecular Diversity, 2021, , 1.	2.1	1
54	Further Studies on Cationic Gemini Amphiphiles as Carriers for Gene Deliveryâ”€The Effect of Linkers in the Structure and Other Factors Affecting the Transfection Efficacy of These Amphiphiles. ACS Omega, 2021, 6, 33370-33388.	1.6	1

#	Article	IF	Citations
55	Design, synthesis and evaluation of 4,7-disubstituted 8-methoxyquinazoline derivatives as potential cytotoxic agents targeting Î²-catenin/TCF4 signaling pathway. Translational Oncology, 2022, 19, 101395.	1.7	0